• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ:REGN)

    748.05 -5.88 (-0.78%)
    Streaming Delayed Price Updated: 12:23 PM EDT, Apr 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Regeneron Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    News headline image
    Telix and Regeneron Announce Strategic Radiopharma Collaboration
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    Regeneron and Telix Announce Strategic Radiopharma Collaboration
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron Announces Investor Conference Presentation
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
    From Society For Science
    Via GlobeNewswire
    News headline image
    Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron Announces Investor Conference Presentations
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
    New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated... 
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Regeneron Announces Investor Conference Presentations
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.